InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,751.07
(
0.90%
)
US TECH 100
19,476.00
(
1.10%
)
Dow Jones
42,352.75
(
0.81%
)
Brent Oil
77.97
(
0.00%
)
Bitcoin
61,816.98
(
-0.41%
)
Post# of 253281
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

rph_in_wi

Send PM Follow Ignore
Followers 1
Posts 115
Boards Moderated 0
Alias Born 10/18/2003

rph_in_wi

Re: DewDiligence post# 3786

Tuesday, 09/28/2004 9:33:41 PM

Tuesday, September 28, 2004 9:33:41 PM

Post# of 253281
"Further study of a 10 mg dose of squalamine is certainly warranted scientifically based on our preliminary results from the MSI-1256F-207 study."

What does that mean? Was it based on adverse events at the higher doses or did the PK info cause Genaera to feel that the drug's distribution/elimination characteristics enabled a lower dose. The statements' ambiguity causes me to lean towards negative assumptions.

Any correction to my thoughts are appreciated.
RPh
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up